ArticleRegenerative therapy2026
Role of WIF-1 in regulating chondrocyte dedifferentiation and matrix production through WNT pathway.
Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chondrocyte dedifferentiation during monolayer expansion is a major barrier to producing clinically reliable cells for cartilage regeneration. The upstream regulators governing this phenotypic instability are not fully defined. This study identifies WNT inhibitory factor 1 (WIF1) as a potential key molecular determinant of chondrocyte stability. Methods: Human auricular chondrocytes (HACs) were expanded to early (P2) and late (P7) passages. Transcriptomic profiling, qPCR, GAG quantification, and histology were performed in 2D monolayer and 3D atelocollagen pellet cultures. WIF1 function was interrogated using lentiviral knockdown and overexpression. β-catenin, Results: Late-passage HACs showed marked dedifferentiation, including reduced WIF1, COL2A1, ACAN, and SOX9 with concomitant increases in COL1A1, ACTA2, and MMP9. WIF1 knockdown in early-passage cells reproduced this phenotype, inducing β-catenin nuclear accumulation, increased SMAD2/3 and JNK activation, diminished GAG synthesis, and loss of cartilage-specific ECM architecture. Conversely, WIF1 overexpression in P7 chondrocytes restored chondrogenic markers, enhanced proteoglycan-rich ECM formation, and suppressed fibroblastic gene expression. WIF1 overexpression re-established a signaling profile resembling early-passage cells, characterized by low β-catenin, reduced Conclusions: WIF1 functions as a critical upstream regulator that maintains chondrocyte identity by simultaneously suppressing WNT/β-catenin, TGF-β/SMAD, and JNK stress signaling. Its loss is a hallmark of dedifferentiation, while its restoration reverses transcriptional drift and rescues ECM-producing capacity. These findings highlight WIF1 as a promising therapeutic target to improve the stability of expanded chondrocytes and enhance the quality of regenerative cartilage constructs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.